Search details
1.
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
N Engl J Med
; 386(19): 1793-1803, 2022 05 12.
Article
in English
| MEDLINE | ID: mdl-35544387
2.
HIV rebound in HIV controllers is associated with a specific fecal microbiome profile.
Eur J Immunol
; : e2350809, 2024 May 10.
Article
in English
| MEDLINE | ID: mdl-38727191
3.
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
N Engl J Med
; 385(25): 2348-2360, 2021 12 16.
Article
in English
| MEDLINE | ID: mdl-34587382
4.
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
N Engl J Med
; 382(13): 1232-1243, 2020 03 26.
Article
in English
| MEDLINE | ID: mdl-32212519
5.
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
Antimicrob Agents Chemother
; 66(6): e0175121, 2022 06 21.
Article
in English
| MEDLINE | ID: mdl-35502922
6.
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1.
Clin Infect Dis
; 72(11): e815-e824, 2021 06 01.
Article
in English
| MEDLINE | ID: mdl-33043969
7.
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Lancet
; 396(10246): 239-254, 2020 07 25.
Article
in English
| MEDLINE | ID: mdl-32711800
8.
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
AIDS Res Ther
; 18(1): 26, 2021 05 03.
Article
in English
| MEDLINE | ID: mdl-33941212
9.
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis.
Clin Infect Dis
; 70(7): 1344-1352, 2020 03 17.
Article
in English
| MEDLINE | ID: mdl-31121015
10.
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.
Clin Infect Dis
; 71(5): 1255-1262, 2020 08 22.
Article
in English
| MEDLINE | ID: mdl-31769793
11.
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial.
J Virol
; 93(21)2019 11 01.
Article
in English
| MEDLINE | ID: mdl-31434737
12.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
AIDS Res Ther
; 16(1): 23, 2019 08 29.
Article
in English
| MEDLINE | ID: mdl-31464642
13.
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.
J Infect Dis
; 217(8): 1280-1288, 2018 03 28.
Article
in English
| MEDLINE | ID: mdl-29325070
14.
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Lancet
; 390(10107): 2073-2082, 2017 Nov 04.
Article
in English
| MEDLINE | ID: mdl-28867499
15.
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Hepatology
; 64(2): 360-9, 2016 08.
Article
in English
| MEDLINE | ID: mdl-26704148
16.
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.
BMC Infect Dis
; 17(1): 389, 2017 06 02.
Article
in English
| MEDLINE | ID: mdl-28577353
17.
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1087-97, 2015 Mar 21.
Article
in English
| MEDLINE | ID: mdl-25467560
18.
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Lancet
; 385(9987): 2606-15, 2015 Jun 27.
Article
in English
| MEDLINE | ID: mdl-25890673
19.
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
N Engl J Med
; 369(22): 2083-92, 2013 Nov 28.
Article
in English
| MEDLINE | ID: mdl-24099601
20.
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Lancet
; 384(9956): 1756-65, 2014 Nov 15.
Article
in English
| MEDLINE | ID: mdl-25078309